A systematic review and meta-analysis of the diagnostic effectiveness of human papillomavirus methylation biomarkers for detection of cervical cancer
Background: The aim of this systematic review and meta-analysis was to assess the evidence for the diagnostic effectiveness of human papillomavirus (HPV) methylation biomarkers for detection of cervical cancer. Methods: PubMed, Embase and Web of Science were searched. Nine articles focusing on HPV methylation for detection of precancerous and cancerous cervical lesions were included. The QUADAS-2 tool was used for quality assessment. The receiver operating characteristic (ROC) was the main diagnostic performance parameter extracted. Results: Of the nine articles included in this study, seven were of moderate quality and two were of high quality. A meta-analysis of the ROC for 27 HPV methylation biomarkers revealed an overall pooled ROC of 0.770 (95% CI: 0.720-0.819; I2: 98.4%; Q: 1537.4; p < 0.01). Four methylation biomarkers had strong diagnostic ability (ROC > 0.900), 17 were moderate (ROC: 0.7000-0.8999) and six were poor (ROC < 0.700). Conclusion: HPV methylation biomarkers hold significant promise as independent screening tests for the detection of cervical precancerous and cancerous lesions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Epigenomics - 14(2022), 18 vom: 07. Sept., Seite 1055-1072 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hillyar, Christopher Rt [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 20.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/epi-2022-0160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34684794X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34684794X | ||
| 003 | DE-627 | ||
| 005 | 20231226032431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/epi-2022-0160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM34684794X | ||
| 035 | |a (NLM)36169190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hillyar, Christopher Rt |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A systematic review and meta-analysis of the diagnostic effectiveness of human papillomavirus methylation biomarkers for detection of cervical cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 20.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The aim of this systematic review and meta-analysis was to assess the evidence for the diagnostic effectiveness of human papillomavirus (HPV) methylation biomarkers for detection of cervical cancer. Methods: PubMed, Embase and Web of Science were searched. Nine articles focusing on HPV methylation for detection of precancerous and cancerous cervical lesions were included. The QUADAS-2 tool was used for quality assessment. The receiver operating characteristic (ROC) was the main diagnostic performance parameter extracted. Results: Of the nine articles included in this study, seven were of moderate quality and two were of high quality. A meta-analysis of the ROC for 27 HPV methylation biomarkers revealed an overall pooled ROC of 0.770 (95% CI: 0.720-0.819; I2: 98.4%; Q: 1537.4; p < 0.01). Four methylation biomarkers had strong diagnostic ability (ROC > 0.900), 17 were moderate (ROC: 0.7000-0.8999) and six were poor (ROC < 0.700). Conclusion: HPV methylation biomarkers hold significant promise as independent screening tests for the detection of cervical precancerous and cancerous lesions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a DNA | |
| 650 | 4 | |a HPV | |
| 650 | 4 | |a ROC | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cervical cancer | |
| 650 | 4 | |a epigenetics | |
| 650 | 4 | |a methylation | |
| 650 | 4 | |a sensitivity | |
| 650 | 4 | |a specificity | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Kanabar, Shivani S |e verfasserin |4 aut | |
| 700 | 1 | |a Pufal, Kamil R |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson, Alexander W |e verfasserin |4 aut | |
| 700 | 1 | |a Saw Hee, Joshua Li |e verfasserin |4 aut | |
| 700 | 1 | |a Rallis, Kathrine S |e verfasserin |4 aut | |
| 700 | 1 | |a Nibber, Anjan |e verfasserin |4 aut | |
| 700 | 1 | |a Sideris, Michail |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epigenomics |d 2009 |g 14(2022), 18 vom: 07. Sept., Seite 1055-1072 |w (DE-627)NLM19811866X |x 1750-192X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:18 |g day:07 |g month:09 |g pages:1055-1072 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/epi-2022-0160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 18 |b 07 |c 09 |h 1055-1072 | ||